discontinue sulfonylurea when starting glp-1 receptor agonist Glucagon-like peptide-1 (GLP-1) agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. receptor agonists and GLP-1 and glucose-dependent insulinotropic GLP-1 Receptor Agonists for the

Combination approaches using GLP-1s with other agents are increasingly common

Inadequate Therapeutic Response: Contact your healthcare provider if you experience minimal or no improvement in target outcomes after reaching your maintenance dose for 12-16 weeks

Relationship between control of glycemia and gastric emptying disturbances in diabetes mellitus

The incidence of antibody formation was 44% with exenatide, 8.6% with liraglutide, 69.8% with lixisenatide, 4% with albiglutide, and 1.6% with dulaglutide [48, 103-106]

105 Other potential combinations include GLP-1 RAs with SGLT-2 inhibitors, 106 amylin analogs, or central nervous system appetite modulators, such as phentermine or bupropion